Relatlimab (Synonyms: BMS-986016) |
رقم الكتالوجGC66381 |
Relatlimab (BMS-986016) هو جسم مضاد أحادي النسيلة بشري مضاد لـ LAG-3 تم إنشاؤه عن طريق تحصين الفئران المعدلة وراثيًا التي تحمل الجلوبيولين المناعي البشري مع بروتين LAG-3 المؤتلف. يمنع Relatlimab تفاعل LAG-3 / MHC II مع قيمة IC50 تبلغ 0.67 نانومتر وتفاعل LAG-3 / FGL1 بقيمة IC50 تبلغ 0.019 نانومتر. يمكن استخدام Relatlimab في أبحاث السرطان.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1673516-98-7
Sample solution is provided at 25 µL, 10mM.
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1].
Relatlimab (BMS-986016; 0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and cynomolgus CD4+ T cells with EC50 values of 0.11 nM and 29.11 nM, respectively[1].
Relatlimab (0.001-10000 nM; T cells (3A9-hLAG-3)) enhances peptide responsiveness of T-cell hybridoma 3A9-hLAG-3 and reversals LAG-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 with an IC50 value of 1.05 nM[1].
Relatlimab (0.001-10000 nM; primary T cells) enhances activation of superantigen-stimulated human PBMC cultures and enhances IL-2 secretion[1].
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *